Genfit SA to Acquire Clinical-Stage Biopharmaceutical Company Versantis AG Call Transcript
Good day, and welcome to the GENFIT conference call.
At this time, I'd like to turn the conference over to Ms. Stefanie Magner. Please go ahead.
Hello, everyone, and thank you for joining us on this conference call organized to follow up on the press release we published this morning. The press release announced that we entered into an exclusivity agreement to acquire Versantis, a private Swiss-based clinical-stage biotechnology company, focused on addressing the growing unmet medical needs in liver diseases. It can be accessed via our website at ir.genfit.com. Joining me on the call today is Pascal Prigent, CEO.
Before we begin, I'd like to remind everyone that statements made during this conference call, including the Q&A session, relating to the group's expected future performance, market potential, business prospects, events or plans, including clinical plans, regulatory approvals, anticipated time lines for clinical development and study
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
